Fosun Pharma has announced its interim results for 2026. In the first half of 2026, the company recorded revenue of RMB 20.442 billion, a Year-on-Year (YoY) increase of 4.75 percent, or 7.17 percent at constant exchange rates. Profit attributable to shareholders of the listed company, net of non-recurring gains and losses, stood at RMB 1.144 billion, up 19.09 percent YoY. Profit growth outpaced revenue growth, reflecting sustained improvement in earnings quality. Net cash generated from operating activities reached RMB 2.424billion, rising 13.59 percent YoY.

Innovation and globalisation stand as the dual core engines driving business performance. Revenue from Innovative Drugs hit RMB 4.911 billion, representing a 13.84 percent YoY increase and accounting for 33.21 percent of pharmaceutical segment revenue, 2.17 percentage points higher than the same period last year. Business revenue from regions outside Chinese mainland and other countries totaled RMB 6.379 billion, growing 16.45 percent YoY and making up 31.21 percent of total revenue, a YoY uplift of 3.14 percentage points. The group's revenue mix continues to improve.

In 1H2026, the company’s total research and development (R&D) investment amounted to RMB 3.247 billion, up 25.66 percent YoY. Among this, R&D investment related to innovative drugs accounted for 81.61 percent of total R&D investment, primarily directed towards pipelines such as HLX43, HLX22, GR1803, FXR0906, as well as next-generation small molecule drugs, radiopharmaceuticals, and other cutting-edge technology platforms.

During the reporting period, Fosun Pharma's innovative drugs entered a period of intensive approvals and value realisation, with a total of 20 indications of 7 innovative drugs were approved for launch both domestically and overseas. In solid tumor areas including lung cancer, breast cancer, and gastrointestinal tumors, the company has established differentiated competitive advantages through multi-product synergy and global commercialisation.

Han Li Kang (Rituximab), Han Qu You (trastuzumab), and Akynzeo continue to maintain leading positions in their respective market segments, consistently contributing stable cash flow.

During H1 2026, Han Si Zhuang (Serplulimab) gained approval in China for the perioperative treatment of gastric cancer, filling a global unmet clinical need. In the European Union (EU), it obtained 3 additional first-line approvals for squamous Non-Small Cell Lung Cancer (NSCLC), esophageal squamous-cell carcinoma and non-squamous NSCLC.

With regulatory applications accepted for multiple innovative drugs and international multi-center clinical trials for key pipelines moving forward efficiently, Fosun Pharma continues to fuel its long-term commercial growth.

In the neurodegenerative diseases field, the integrated diagnosis and treatment layout continues to strengthen. The post-marketing confirmatory clinical trial for Sodium Oligomannate Capsules in Chinese mainland is progressing steadily; as of July 31, 2026, cumulative enrollment exceeded 1,000 cases, reaching over 50 percent of the planned enrollment target. HT001, an investigational drug for Parkinson's disease, has initiated phase 1 clinical trials in Australia. Parallel work is underway on the clinical deployment of magnetic-resonance-guided focused-ultrasound therapy and the R&D of companion diagnostic reagents.

Rooted in evidence-based medicine, Fosun Pharma presented 3 oral abstracts at the 2026 ASCO Annual Meeting, including the phase 3 study of Fu Mai Ning in adult NF1 patients, the phase 3 study of serplulimab injection in the perioperative setting for gastric cancer, and the clinical study of HLX43 in NSCLC.

Ten studies were selected for poster presentations at the 2026 ASCO Annual Meeting, including data from two phase 3 studies of Fu Tuo Ning and a study of HLX43 in nasopharyngeal carcinoma. The company continues to deliver high-quality clinical outcomes in top-tier global journals such as The Lancet and Nature Medicine, as well as at global industry academic conferences, providing solid academic support for international registration and commercial expansion of its products.

In terms of out-licensing, Shanghai Henlius, a subsidiary of Fosun Pharma, has entered strategic partnerships with Eisai and Abbott for serplulimab. Eisai obtains development, manufacturing and exclusive commercialisation rights for Japan and agreed territories. Abbott receives exclusive commercial-license rights covering 42 countries and regions across Asia, the Middle East, Africa and Eastern Europe. These collaborations accelerate global roll-out of home-grown innovations for patients worldwide.

In terms of in-licensing, Fosun Pharma entered into a global exclusive option agreement with AriBio for AR1001, an investigational drug for Alzheimer's disease. Building on the existing rights in China and Southeast Asia, Fosun Pharma is entitled to further expand its right to global core markets including the US, Europe, and Japan, with the company serving as the Marketing Authorisation (MA) holder for the product in the corresponding territories. The international multi-center phase 3 clinical trial of AR1001 for the treatment of early Alzheimer's disease has completed the last patient's last visit, with top-line results to be announced within 2026.

Chen Yuqing, Chairman, Fosun Pharma, said, "Amidst challenging industry dynamics, Fosun Pharma responded to external uncertainties with strategic focus, achieving steady revenue growth. We stay firmly committed to innovation and globalisation. Concentrating on oncology, immuno-inflammation and neurodegenerative diseases, we leverage our global footprint and 2-way BD synergies to build stronger commercial capabilities. Amid global-expansion opportunities for China's innovative drugs, we take a long-term view and advance resolutely toward high-quality development."